CR7854A - Dihidrofenantridinosulfonamidas sustituidas - Google Patents
Dihidrofenantridinosulfonamidas sustituidasInfo
- Publication number
- CR7854A CR7854A CR7854A CR7854A CR7854A CR 7854 A CR7854 A CR 7854A CR 7854 A CR7854 A CR 7854A CR 7854 A CR7854 A CR 7854A CR 7854 A CR7854 A CR 7854A
- Authority
- CR
- Costa Rica
- Prior art keywords
- dihydrophenantridinosulphonamids
- substituted
- arthritis
- diseases
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion proporciona un compuesto de las formulas (I) o (II) que tiene la estructura o una sal farmaceuticamente aceptable de el que son utiles para el tratamiento del componente inflamatorio de enfermedades y son particularmente utiles en el tratamiento de aterosclerosis, infarto de miocardio, inflamatoria, artritis, diabetes tipo II, y enfermedades autoinmunes como esclerosis multiple y artritis reumatoide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43094902P | 2002-12-04 | 2002-12-04 | |
US10/718,461 US6894061B2 (en) | 2002-12-04 | 2003-11-20 | Substituted dihydrophenanthridinesulfonamides |
Publications (1)
Publication Number | Publication Date |
---|---|
CR7854A true CR7854A (es) | 2006-04-28 |
Family
ID=32474616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR7854A CR7854A (es) | 2002-12-04 | 2005-06-02 | Dihidrofenantridinosulfonamidas sustituidas |
Country Status (19)
Country | Link |
---|---|
US (1) | US6894061B2 (es) |
EP (1) | EP1567502B1 (es) |
JP (1) | JP4465280B2 (es) |
KR (1) | KR20050085321A (es) |
AT (1) | ATE370934T1 (es) |
AU (1) | AU2003298819A1 (es) |
BR (1) | BR0316196A (es) |
CA (1) | CA2508329A1 (es) |
CR (1) | CR7854A (es) |
DE (1) | DE60315874T2 (es) |
DK (1) | DK1567502T3 (es) |
EC (1) | ECSP055832A (es) |
ES (1) | ES2291739T3 (es) |
MX (1) | MXPA05006003A (es) |
NO (1) | NO20053204L (es) |
NZ (1) | NZ540440A (es) |
RU (1) | RU2005118070A (es) |
TW (1) | TW200510322A (es) |
WO (1) | WO2004050631A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050119276A1 (en) * | 2003-09-24 | 2005-06-02 | Wyeth | Methods of treating inflammatory bowel disease using NF-kB inhibitors |
US20050113405A1 (en) * | 2003-09-24 | 2005-05-26 | Wyeth | Methods of treating rheumatoid arthritis using NF-kB inhibitors |
EP1652841A1 (en) * | 2004-04-30 | 2006-05-03 | Switch Biotech Aktiengesellschaft | Novel phenantridine analogues and their use as inhibitors of hyperproliferation of T cells and/or keratinocytes |
AU2005265093A1 (en) * | 2004-06-18 | 2006-01-26 | Wyeth | Processes for preparing 6-alkyl-5-arylsulfonyl- dihydrophenanthridines |
US7304073B2 (en) * | 2004-08-20 | 2007-12-04 | Wyeth | Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors |
RU2007108713A (ru) * | 2004-09-02 | 2008-10-10 | Вайет (Us) | Фенантридинкарбонилфенолы в качестве модуляторов цитокина |
AU2006206534A1 (en) * | 2005-01-19 | 2006-07-27 | Wyeth | Estrogen receptor structure |
HU230518B1 (hu) * | 2005-12-20 | 2016-10-28 | Richter Gedeon Nyrt. | Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények |
TW200829578A (en) | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
TW200848021A (en) | 2007-03-06 | 2008-12-16 | Wyeth Corp | Sulfonylated heterocycles useful for modulation of the progesterone receptor |
EP2520561B1 (en) | 2007-06-08 | 2016-02-10 | MannKind Corporation | IRE-1A Inhibitors |
SA109300309B1 (ar) | 2008-05-20 | 2013-01-22 | باير شيرنج فارما ايه جي | مشتقات فينيل وبنزو داي أوكسينيل إندازول بها استبدال |
US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションLycera Corporation | RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションLycera Corporation | RORγの作動薬及び疾患の療法として使用するジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物 |
MX2017016134A (es) | 2015-06-11 | 2018-08-15 | Lycera Corp | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. |
WO2020117894A1 (en) * | 2018-12-05 | 2020-06-11 | The Board Of Trustees Of The University Of Illinois | Isocarbostyril alkaloids and functionalization thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1135947A (en) | 1965-04-20 | 1968-12-11 | Aspro Nicholas Ltd | Novel biologically active derivatives of phenanthridone |
EP0509756A1 (en) | 1991-04-16 | 1992-10-21 | Merck & Co. Inc. | 2-Phenanthridonyl carbapenems having cationizeable substituents |
CA2066132A1 (en) | 1991-04-16 | 1992-10-17 | Thomas A. Rano | 2-phenanthridonyl carbapenems |
US5153185A (en) | 1991-04-16 | 1992-10-06 | Merck & Co., Inc. | 2-phenanthridonyl carbapenems |
US5726186A (en) | 1995-09-08 | 1998-03-10 | Eli Lilly And Company | Pentacyclic compounds, intermediates, processes, compositions, and methods |
JP2001510827A (ja) | 1997-07-25 | 2001-08-07 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 置換6−フェニルフェナントリジン |
CN1152864C (zh) | 1999-01-15 | 2004-06-09 | 奥坦纳医药公司 | 具有pde-iv抑制活性的苯基菲啶类化合物 |
EP1163226B1 (en) | 1999-01-15 | 2007-03-14 | ALTANA Pharma AG | Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
AU2001281965A1 (en) | 2000-07-14 | 2002-01-30 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Novel 6-phenylphenanthridines |
AU2001288623A1 (en) | 2000-09-05 | 2002-03-22 | Tularik, Inc. | Fxr modulators |
-
2003
- 2003-11-20 US US10/718,461 patent/US6894061B2/en not_active Expired - Fee Related
- 2003-12-02 BR BR0316196-0A patent/BR0316196A/pt not_active IP Right Cessation
- 2003-12-02 AU AU2003298819A patent/AU2003298819A1/en not_active Withdrawn
- 2003-12-02 NZ NZ540440A patent/NZ540440A/en unknown
- 2003-12-02 WO PCT/US2003/038290 patent/WO2004050631A1/en active IP Right Grant
- 2003-12-02 ES ES03796577T patent/ES2291739T3/es not_active Expired - Lifetime
- 2003-12-02 JP JP2004557494A patent/JP4465280B2/ja not_active Expired - Fee Related
- 2003-12-02 EP EP03796577A patent/EP1567502B1/en not_active Expired - Lifetime
- 2003-12-02 CA CA002508329A patent/CA2508329A1/en not_active Abandoned
- 2003-12-02 RU RU2005118070/04A patent/RU2005118070A/ru not_active Application Discontinuation
- 2003-12-02 DE DE60315874T patent/DE60315874T2/de not_active Expired - Lifetime
- 2003-12-02 KR KR1020057010047A patent/KR20050085321A/ko not_active Application Discontinuation
- 2003-12-02 AT AT03796577T patent/ATE370934T1/de not_active IP Right Cessation
- 2003-12-02 MX MXPA05006003A patent/MXPA05006003A/es active IP Right Grant
- 2003-12-02 DK DK03796577T patent/DK1567502T3/da active
- 2003-12-04 TW TW092134185A patent/TW200510322A/zh unknown
-
2005
- 2005-06-02 EC EC2005005832A patent/ECSP055832A/es unknown
- 2005-06-02 CR CR7854A patent/CR7854A/es not_active Application Discontinuation
- 2005-06-30 NO NO20053204A patent/NO20053204L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2006510631A (ja) | 2006-03-30 |
JP4465280B2 (ja) | 2010-05-19 |
DE60315874D1 (de) | 2007-10-04 |
US6894061B2 (en) | 2005-05-17 |
WO2004050631A1 (en) | 2004-06-17 |
ECSP055832A (es) | 2005-08-11 |
US20040167155A1 (en) | 2004-08-26 |
NZ540440A (en) | 2006-11-30 |
DK1567502T3 (da) | 2007-10-29 |
DE60315874T2 (de) | 2008-05-15 |
BR0316196A (pt) | 2005-09-27 |
CA2508329A1 (en) | 2004-06-17 |
NO20053204D0 (no) | 2005-06-30 |
NO20053204L (no) | 2005-09-05 |
AU2003298819A1 (en) | 2004-06-23 |
RU2005118070A (ru) | 2006-01-27 |
ATE370934T1 (de) | 2007-09-15 |
ES2291739T3 (es) | 2008-03-01 |
EP1567502B1 (en) | 2007-08-22 |
KR20050085321A (ko) | 2005-08-29 |
EP1567502A1 (en) | 2005-08-31 |
TW200510322A (en) | 2005-03-16 |
MXPA05006003A (es) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055832A (es) | Dihidrofenantridinosulfonamidas sustituidas | |
MXPA05011581A (es) | Derivados de acido 3-(1-naftil)-2-cianopropanoico como ligandos receptores de estrogenos. | |
DE60333387D1 (de) | Triazolopyridazine als proteinkinase-inhibitoren | |
NO20083743L (no) | Pyrimidinylsulfonamidforbindelser som inhiberer leukocyttadhesjon mediert av VLA-4 | |
BR0311343A (pt) | Derivados de piridazina | |
PA8571001A1 (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
TR200201187T2 (tr) | Ters transkriptazın inhibitörleri olarak benzofenonlar | |
CY1110177T1 (el) | Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης | |
BR9811599A (pt) | Compostos de dipetìdeo que inibem adesão de leucócito mediada por vla-4 | |
EA200501274A1 (ru) | Пиразолы и способы их получения и применения | |
DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
NO20000450L (no) | Substituerte fenylalaninforbindelser som inhiberer leukocytt- adhesjon mediert av VLA-4 | |
DE60226154D1 (de) | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung | |
DE60238620D1 (de) | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung | |
NO20082002L (no) | Pyrimidinylamidforbindelser som inhiberer leukocyttadhesjon mediert ved VLA-4 | |
DK1507775T3 (da) | Heterocykliske forbindelser som hæmmer leukocyt-adhæsion medieret af alfa-4-integriner | |
UA85559C2 (en) | Aminobenzophenone compounds | |
AU3864500A (en) | Substituted aza-oxindole derivatives | |
NO20070089L (no) | DPP-IV inhibitorer | |
DK1562954T3 (da) | CCR1-antagonister til behandling af I.A. inflammatorisk demyelinisationssygdom | |
PT1334094E (pt) | Benzo[b]tiofenos e benzo(d)isotiazoles para diminuir o colesterol | |
CL2004001507A1 (es) | Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras. | |
ATE276259T1 (de) | Dihydroporphyrinderivate und ihre verwendung | |
WO2004056762A3 (en) | Novel aminobenzophenone compounds | |
NO20065200L (no) | Dialkoksy-imidazopyridinderivater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |